Mode
Text Size
Log in / Sign up

Meta-analysis finds modest PTS reduction with compression stockings after DVT

Meta-analysis finds modest PTS reduction with compression stockings after DVT
Photo by Brett Jordan / Unsplash
Key Takeaway
Consider compression stockings for modest PTS reduction after DVT, noting low certainty and uncertain severe effects.

This is a meta-analysis of studies on patients with deep vein thrombosis, assessing the effect of long-term graduated compression stockings on post-thrombotic syndrome (PTS). The review synthesized data from 1,775 patients and found a modest reduction in total PTS incidence (RR 0.70; 95% CI 0.51–0.96), corresponding to an absolute reduction of approximately 127 per 1,000. A reduction was also seen for mild-to-moderate PTS (RR 0.69; 95% CI 0.50–0.93), with an absolute reduction of about 129 per 1,000.

Effects on severe PTS were uncertain (RR 0.56; 95% CI 0.22–1.43). The stockings had no clear impact on recurrent DVT (RR 0.90; 95% CI 0.73–1.11) or all-cause mortality (RR 0.98; 95% CI 0.68–1.40). The authors noted low certainty for total and mild-to-moderate PTS, and very low certainty for severe PTS, recurrent DVT, and mortality.

Key limitations included heterogeneity in adherence, control group design, PTS definitions, and initial DVT management, which may have influenced outcomes. Safety data were not reported. The authors concluded that clinical decisions should consider patient-specific factors, adherence, and the multifactorial determinants of PTS.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundPost-thrombotic syndrome (PTS) is a common long-term complication following deep vein thrombosis (DVT), leading to substantial morbidity and impaired quality of life. Elastic compression stockings (ECS) are widely used for PTS prevention; however, their effectiveness remains controversial, particularly across different severities of PTS.MethodA systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the effectiveness of ECS in preventing PTS after DVT. Electronic databases were searched from inception to January 20, 2026. The primary outcomes were the overall incidence of PTS at final follow-up, as well as the incidence of mild-to-moderate and severe PTS. Secondary outcomes included recurrent DVT and all-cause mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. The certainty of evidence was assessed using the GRADE approach.ResultsEight trials involving 1,775 patients were included. ECS were associated with a modest reduction in total PTS (RR 0.70; 95% CI 0.51–0.96; absolute reduction ~127 per 1,000), corresponding to an absolute reduction of approximately 142 cases per 1,000 patients. When stratified by severity, ECS reduced mild-to-moderate PTS (RR 0.69; 95% CI 0.50–0.93; absolute reduction ~129 per 1,000), whereas effects on severe PTS were uncertain (RR 0.56; 95% CI 0.22–1.43). No clear impact was observed on recurrent DVT (RR 0.90; 95% CI 0.73–1.11) or all-cause mortality (RR 0.98; 95% CI 0.68–1.40). Certainty of evidence was low for total and mild-to-moderate PTS and very low for severe PTS, recurrent DVT, and mortality. Heterogeneity in adherence, control group design, PTS definitions, and initial DVT management may have influenced outcomes.ConclusionLong-term ECS may modestly reduce mild-to-moderate PTS after DVT, but their effect on severe PTS, recurrent DVT, and mortality remains uncertain. ECS may improve symptoms, but their preventive effect is limited, and clinical decisions should consider patient-specific factors, adherence, and the multifactorial determinants of PTS.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261386069.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.